Napro Biotherapeutics (NASDAQ:NPRO)
Historical Stock Chart
From Jun 2019 to Jun 2024
![Click Here for more Napro Biotherapeutics Charts. Click Here for more Napro Biotherapeutics Charts.](/p.php?pid=staticchart&s=N%5ENPRO&p=8&t=15)
NaPro Announces Formation of Oncology Scientific Advisory Board
BOULDER, Colo., April 27 /PRNewswire-FirstCall/ -- NaPro BioTherapeutics, Inc.
today announced the formation of an Oncology Scientific Advisory Board to
advise the company on the clinical development of its proprietary new drug
candidates for the treatment of cancer. Paul A. Bunn, Jr., M.D., a member of
the Company's Scientific Advisory Board, will serve as the Chair of the
Oncology Scientific Advisory Board.
"Our development team at NaPro is looking forward to working closely with Dr.
Bunn and the other members of our new Oncology Advisory Board as we advance our
new product candidates into the clinic. We welcome their close scrutiny and
counsel," commented Leonard P. Shaykin, Chairman and Chief Executive Officer of
NaPro.
Brief backgrounds of the members of the Oncology Advisory Board are given
below:
Paul A. Bunn, Jr., M.D. (Chairman): Dr. Bunn is the Director of the University
of Colorado Cancer Center, previous president (2002-2003) of the American
Society of Clinical Oncology (ASCO), and former chairman of the Oncology Drugs
Advisory Committee (ODAC) of the FDA. Dr. Bunn is an authority in the field of
clinical oncology with a research specialty in lung cancer. Dr. Bunn received
his M.D. from Cornell University Medical College.
S. Gail Eckhardt, M.D.: Dr. Eckhardt is a Professor of Medicine and the
Director of the Developmental Therapeutics and GI Malignancies Programs at the
University of Colorado Health Science Center in Denver. She is a member of the
ASCO Board of Directors and ASCO Publications Committee. She previously worked
as an Associate Director of Clinical Research, Cancer Therapy and Research
Center at the Institute for Drug Development in San Antonio, Texas. Dr.
Eckhardt received her M.D. from the University of Texas Medical Branch in
Galveston.
Eric K. Rowinsky, M.D.: Dr. Rowinsky is the Director of the Institute for Drug
Development, Cancer Therapy and Research Center and Clinical Professor of
Medicine at the University of Texas Health Science Center at San Antonio. He
serves as the Editor-in-Chief of Investigational New Drugs and as an Associate
Editor for various publications, including Cancer Research. Dr. Rowinsky also
serves on the NCI Board of Scientific Counselors. He is actively involved in
preclinical and clinical research in anticancer drug development and has played
pivotal roles in the regulatory approval of a large number of contemporary
anticancer therapeutics such as Taxotere(R). Dr. Rowinsky received his M.D.
from the Vanderbilt School of Medicine.
Daniel D. Von Hoff, M.D.: Dr. Von Hoff is Professor of Medicine, Pathology,
Molecular and Cellular Biology and the Director of the Arizona Health Sciences
Center's Cancer Therapeutics Program. He is, also, Director of Translational
Research at the Translational Genomics Research Institute (TGen). He is Chief
Scientific Officer for US Oncology, Inc. and a founder and board member of ILEX
Oncology, Inc. Dr. Von Hoff has been involved in the initial development of
many anticancer agents, including paclitaxel, docetaxel, gemcitabine and
CPT-11. He is currently concentrating on the development of molecularly
targeted therapies. Dr. Von Hoff received his M.D. from Columbia University.
About NaPro BioTherapeutics
NaPro BioTherapeutics, Inc. is a pharmaceutical company focused on the
development of therapies for the treatment of cancer and hereditary disease.
For more information about NaPro and its technologies, visit NaPro's web site
at http://www.naprobio.com/.
Forward Looking Statements
The statements in this press release that are not historical facts are
forward-looking statements that represent management's beliefs and assumptions
as of the date of the press release, based on currently available information.
Forward-looking statements can be identified by the use of words such as
"believes," "intends," "estimates," "may," "will," "should," "anticipates,"
"expected" or comparable terminology or by discussions of strategy, and include
statements regarding the Company's advancing new product candidates into the
clinic and the nature of scrutiny and counsel by the Oncology Advisory Board.
Although the Company believes that the expectations reflected in such
forward-looking statements are reasonable, it cannot assure that these
expectations will prove to be correct. Such statements involve risks and
uncertainties including those factors identified under the captions "Risk
Factors," "Special Note Regarding Forward Looking Statements" or "Cautionary
Note Regarding Forward Looking Statements" in the Company's documents filed
from time to time with the SEC, including the Company's Annual Report on Form
10-K for the year ending December 31, 2003 filed with the SEC on March 11,
2004. Should one or more of these risks materialize (or the consequences of
such a development worsen), or should the underlying assumptions prove
incorrect, actual results could differ materially from those forecasted or
expected. The Company disclaims any intention or obligation to update publicly
or revise such statements whether as a result of new information, future events
or otherwise.
For further information, please contact L. Robert Cohen, Vice President,
Investor Relations of NaPro BioTherapeutics, Inc., +1-212-218-8715.
DATASOURCE: NaPro BioTherapeutics, Inc.
CONTACT: L. Robert Cohen, Vice President, Investor Relations of NaPro
BioTherapeutics, Inc., +1-212-218-8715; or investors, Lilian Stern of Stern
Investor Relations, Inc., +1-212-362-1200, or media, Peter Steinerman,
+1-516-374-3031, both for NaPro BioTherapeutics, Inc.
Web site: http://www.naprobio.com/